Carfilzomib-d8, CAS 1537187-53-3

Product Description: Carfilzomib-d8 is deuterium labeled Carfilzomib. Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.

Applications: Cancer-Kinase/protease

Formula: C40H49D8N5O7

References: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216./[2]Dasmahapatra G, et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2011 Sep;10(9):1686-97./[3]Kuhn DJ, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110(9):3281-90.

CAS Number: 1537187-53-3

Molecular Weight: 727.96

Compound Purity: 98.93

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Apoptosis;Autophagy;Isotope-Labeled Compounds;Proteasome

• Artikelnummer: MEXHY-10455S-500UG
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-10455S-500UG
• Verpackungseinheit: 500 μg
• Mengeneinheit: STK